Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Arrowhead Publishers | Evidence-Based Medicine Current Use and Future Impact on Global Clinical and Reimbursement Practices

Evidence-Based Medicine Current Use and Future Impact on Global Clinical and Reimbursement Practices

Evidence-based medicine is defined as an attempt to use standards from scientifically-collected evidence to improve medical practices by assessing risks and benefits of treatments and/or the lack of treatments. The term can be taken to cover a wide variety of recommendations and guidelines, as well as the basis for decisions regarding pharmaceutical reimbursement. This one-of-a-kind report discusses evidence-based medicine in a variety of its guises, illustrating the pervasive nature of evidence-based decisions in healthcare and pharmaceutical environments.

In recent years, evidence-based medicine has emerged as one of the most pertinent topics of discussion within the field of medicine, involving – on the one hand - patients and – on the other - a variety of healthcare policy-makers, practitioners and regulators. In the United Kingdom, evidence-based practice has been implemented in a variety of fields, including adult medicine, child health, surgery, pathology, pharmacotherapy, nursing, general practice, and dentistry, as well as in the field of pharmaceutical reimbursement. Evidence-based medicine has also been practiced by the governments of Canada and Australia for some time, while Germany, Japan and the United States have more recently begun to utilize evidence-based medicine for both private and public reimbursement.

The opening chapters of this report provide a brief history of evidence-based medicine, main definitions and the limitations and advantages of the concept. Subsequent chapters discuss the use and applicability of evidence-based medicine in various therapeutic areas, followed by a discussion of evidence-based medicine in six major global medical and pharmaceutical markets. The first three of these (namely Australia, Canada and the United Kingdom) are seen as pioneers in the utilization of evidence-based medicine, while the other three (namely Germany, Japan and the United States) have more recently become interested in wider applicability of such practices.

The final chapter discusses the future prospects for evidence-based medicine, setting out, on the one hand, the list of factors driving wider application of such practices. On the other, the report analyses a number of constraints to the use of evidence-based medicine, which include a range of practical considerations, such as a lack of time and information overload, as well as more culture-specific resistance to compliance with imposed guidelines.

What questions does this report answer?

* What is the current status of evidence-based medicine in key global markets?

* What are the major drivers of wider application of evidence-based medicine?

* What types of evidence-based medicine strategies are currently in use in various countries around the world?

* What is the anticipated future for evidence-based medicine practices?

* How will the development of expensive new therapeutics stimulate the need for the implementation of evidence-based medicine?

Highlights of this report

* Discussion of evidence-based medicine in pharmaceutical reimbursement in a number of key global markets

* Discussion of the future of evidence-based medicine in light of medical and scientific developments

* Focused analysis of various evidence-based medicine developments in the US

* Identification of key evidence-based medicine resources

* Contributions from industry experts highlighting country-specific cultural constraints to wider penetration of evidence-based medicine

Key reasons to purchase this report

* The report provides an analytically-focused guide to the global application of evidence-based medicine

* The report provides a comparison of evidence-based medicine and its applicability in different countries

* The report provides a scenario for the future use of evidence-based medicine through the discussion of drivers and constraints

* The report identifies key resources and organizations involved in the formulation of evidence-based medicine policies

What makes this report topical?

* Increasing need for healthcare and pharmaceutical cost-containment in both public and private spheres

* Focus on introduction of standards in healthcare

* Rising involvement of patients in their own healthcare and rising demand for higher quality care

* Increasing use of information technology (IT) in healthcare, which provides easier access to various data and analysis

* Large investments in new medical technologies and pharmaceuticals requiring high prices, rendering publicly-funded pharmaceutical reimbursement highly desirable

Unique features of this report

* Thorough descriptions of key evidence-based medicine practices in major global medical and pharmaceutical markets

* Discussion of evidence-based medicine’s future from the point of view of medical advances, not just practical considerations

* Analysis of evidence-based medicine from the point of view of pharmaceutical reimbursement

* Critical assessment of evidence-based medicine’s advantages and disadvantages

Publication Date: May 19, 2008

Pages: 181

Format: PDF

Table of Contents

Price

Single User PDF $2999.00

Site / Department Licence PDF $5999.00

Company-wide license PDF $8999.00

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions